Printer Friendly

Sun Pharma Announces USFDA Approval for Generic Xanax[R] Tablets.

MUMBAI, India -- Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax[R], alprazolam tablets.

These generic alprazolam tablets, equivalent to Pfizer's Xanax[R] tablets, include four strengths: 0.25 mg, 0.5 mg, 1 mg and 2 mg. Annual sale in US for these strengths of branded and generic alprazolam tablets is estimated at $145 million.

Alprazolam tablets are indicated for the management of anxiety disorder or the short-term relief of symptoms of anxiety. It is also indicated for the treatment of panic disorder, with or without agoraphobia.

Xanax[R] is a registered trademark of Pfizer.

About Sun Pharmaceutical Industries Ltd.

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, diabetology, gastroenterology, orthopedics and ophthalmology. The Company has strong skills in product development, process chemistry, and manufacturing of complex API, as well as dosage forms. More information about the company can be found at www.sunpharma.com.
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:9INDI
Date:Jun 18, 2010
Words:225
Previous Article:Research and Markets: Financial Analysis - Flowserve Corporation.
Next Article:Office Ally Stages Intensive Internal Audit for Meaningful Use.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters